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MicroRNA-34 (miR-34) is directly regulated by p53, and its potential tumor suppressive roles have been studied
extensively. As a p53-induced microRNA, miR-34 functions as a tumor suppressor by playing a role in cell cycle
arrest, apoptosis and metabolic regulation. Among these p53/miR-34 associated processes, apoptosis and cell cycle
arrest are known as essential for p53/miR-34-mediated tumor suppression. P53-mediated metabolic processes have
been shown to play pivotal roles in cancer cell biology. Recent studies have also identified several miR-34 targets
involved in p53/miR-34-induced metabolic regulation. However, correlations among these metabolic targets remain
to be fully elucidated. In this review, we summarize the current progress in the field of metabolic regulation by the
p53/miR-34 axis and propose future directions for the development of metabolic approaches in anticancer therapy.
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MicroRNAs (miRNAs) are small noncoding RNAs that
regulate gene expression by binding to complementary se-
quences in the 3’UTR of mRNAs. The identification of the
first miRNA, Lin-4, which was found in worms [1], was
followed by an increasing interest in understanding the
realm of small noncoding RNAs. Aberrant regulation of
miRNAs is found in many types of human cancer [2,3]. A
number of studies have shown that miRNAs can regulate
apoptosis, cell proliferation and epithelial-mesenchymal
transition in cancer cells [4-7]. Here, we focus on the
miR-34 family and investigate the therapeutic potential of
p53/miR-34-induced metabolic regulation for the treat-
ment of cancer.
The miR-34 family includes miR-34a, miR-34b and
miR-34c, which are encoded by two different genes. MiR-
34a is encoded by its own transcript, while miR-34b and
miR-34c share a common primary transcript. Members of
the miR-34 family have tissue-specific functions, as miR-
34a is expressed in the brain, whereas miR-34b/c is largely
expressed in the lungs [8,9]. Studies have shown that aber-
rant expression of the three miR-34 members exists in
many cancers [9-16]. MiR-34 genes that are directly* Correspondence: jnzheng@xzmc.edu.cn; dspei@xzmc.edu.cn
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unless otherwise stated.regulated by p53 have been identified [8,17,18], and their
involvement in p53-mediated cellular responses associated
with tumor suppression such as apoptosis [17,19], cell
cycle arrest [20,21] and metabolic regulation [22] has been
demonstrated. The promotion of apoptosis along with the
induction of cell cycle arrest, which are pivotal for p53-
mediated tumor suppression, were the first outcomes
observed after the ectopic expression of miR-34 [20]. A
number of direct miR-34 targets, including B-cell CLL/
lymphoma 2 (Bcl-2), baculoviral IAP repeat containing 5
and silent information regulator 1 (SIRT1), are related to
cellular apoptosis [23]. Another class of miR-34 targets in-
cluding v-myc avian myelocytomatosis viral oncogene
homolog (MYC), E2F transcription factor 3 and cyclin E2
are involved in the induction of G1 arrest [10,11,24], and
miR-34 targets associated with metabolic regulation gov-
erned by p53 have also been identified [22,25]. P53/miR-
34-mediated apoptosis and cell cycle arrest have been
studied extensively, whereas metabolic regulation through
the p53/miR-34 axis is not fully understood, in particular
the correlations among miR-34-induced metabolic targets.
Recently, an increasing number of studies have shown an
association between metabolism and p53, which indicates
that metabolic regulation may play a critical role in p53-
induced tumor suppression and suggests that the roles of
metabolism and canonical processes of p53 in human can-
cer need further evaluation [26,27]. In addition, miR-34Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ders [28-30]. In the present review, we summarize the evi-
dence and research progress in metabolic regulation
mediated by p53/miR-34 to shed light on the potential of
the p53/miR-34 axis as a therapeutic target for the treat-
ment of cancer.
Tumor suppressive roles of p53-mediated
metabolism
Studies have shown that the metabolic targets of p53 are
associated with glycolysis [31-34], mitochondrial respir-
ation [35] and lipid metabolism [36]. Regarding p53
function, cell cycle arrest and apoptosis have been studied
extensively and recognized as essential for p53-induced
tumor suppression. However, recent studies found that
these canonical processes are not the rate-limiting steps in
tumor suppression and suggested metabolic regulation as
a crucial step for early-onset spontaneous tumorigenesis
[26,27]. They generated mice bearing lysine to arginine
mutations at one (p53K117R) or three (p533KR; K117R +
K161R + K162R) p53 acetylation sites and found that p53-
mediated cell cycle arrest and apoptosis were abrogated by
the loss of acetylation at all three sites. Interestingly, early-
onset tumor formation did not occur in animals carrying
either mutation, suggesting that the combined loss of p53-
dependent cell cycle arrest, apoptosis and senescence was
inadequate to abolish the p53-mediated tumor suppres-
sion. The fact that p533KR retains the ability to regulate
the expression of metabolic p53 target genes, together
with data on glucose uptake and glycolysis tests, led the
authors to suggest that p533KR retains its activity at least
partly through the regulation of energy metabolism levels
in vivo. Further evidence was provided by additional
studies in which they generated mice deficient in the p53
proapoptotic effectors p21, Puma and Noxa [27], the ex-
pression of which was only reduced rather than abrogated
in the former study. This study also confirmed that
instead of cell cycle arrest and apoptosis, metabolic regu-
lation might be critical for p53-mediated tumor suppres-
sion. These results provided a new angle to further
investigate the mechanism underlying the function of p53
in tumor suppression.
Feedback loops in the p53/microRNA-34 network
In 2007, miR-34 family members were reported to be
direct p53 targets and shown to induce apoptosis and
cell cycle arrest [17,18]. Further studies indicated that
miR-34 functions as a tumor suppressive miRNA and
plays a role in the regulation of p53 expression, and in
turn p53 directly regulates miR-34 and thereby induces
cellular processes associated with tumor suppression.
MiR-34 can repress SIRT1 [30], histone deacetylase 1
(HDAC1) [22,37] and the transcriptional factor YY1
[22,38,39], and thereby forms positive feedback loops forp53 activation. An increasing number of miR-34 targets
have been identified and many of them are associated
with tumor suppression, with most of them governed by
p53. P53/miR-34-mediated tumor suppressive processes
include apoptosis and cell cycle arrest, stemness, metas-
tasis and metabolism [40-43]. Among these cellular re-
sponses, apoptosis and G1 arrest were the first processes
associated with ectopic expression of miR-34 and have
been studied extensively. However, other p53/miR-34-in-
duced processes such as metabolic regulation remain to
be fully elucidated.
Collaboration of p53/microRNA-34 targets in
metabolic regulation
Several miR-34 targets are associated with metabolic pro-
cesses, among which lactate dehydrogenase A (LDHA),
MYC and SIRT1 are of central importance [10,22,25,44].
These three direct miR-34 targets have tight connections
with one another and function collaboratively in p53/miR-
34-mediated metabolic regulation.
Numerous tumor suppressors and oncogenes are closely
associated in metabolic pathways, and the first docu-
mented mechanism involving an activated oncogene in
altered glucose metabolism was the transcriptional activa-
tion of LDHA by the oncogenic transcription factor MYC
[45]. LDHA catalyzes the conversion of pyruvate to lactate
and is considered to play a key role in anaerobic glycolysis
[46]. The level of LDHA is elevated in many human can-
cers in correlation with tumor proliferation and malignant
growth [47,48]. MYC is frequently altered in human can-
cer and has been reported to regulate many glucose me-
tabolism genes, such as glucose transporter GLUT1 and
hexokinase 2 (HK2) [49]. The regulation of cell size, pro-
liferation and cellular metabolism by MYC was proposed
to occur in a miR-34-dependent manner [10,49,50]. MYC
was shown to transactivate the LDHA promoter and dir-
ectly increase LDHA expression, which suggested that
LDHA is a direct target of MYC. Furthermore, the ele-
vated expression of LDHA may be necessary for MYC-
mediated transformation [45]. LDHA was also shown to
be a common target of MYC and the hypoxia inducible
factors (HIFs) [51]. HIFs, as well as MYC, are pivotal
factors for tumorigenesis in many types of human cancers
and are able to activate LDHA [52,53]. The ectopic
expression of MYC promotes its collaboration with HIF
to confer metabolic advantages to tumor cells, which
partly contributes to the Warburg effect [51,54]. In this
process, the expression of LDHA is activated by both
MYC and HIFs. Further studies showed that alterations of
LDHA expression lead to changes in cancer metabolism
[47,55-57].
Another miR-34 target, SIRT1, also plays a critical role in
p53/miR-34-induced metabolism. SIRT1 is a multifaceted
NAD+-dependent protein deacetylase that deacetylates
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inhibits SIRT1 expression, resulting in a reduction of p53
deacetylation [25]. Thus, SIRT1, p53 and miR-34 form a
positive feedback loop to induce tumor suppression. Add-
itionally, SIRT1 can inhibit the miR-34 promoter through
histone deacetylation [59].
Close associations between SIRT1 and LDHA have been
described, and SIRT1 activity is largely determined by
LDHA. SIRT1 is a NAD+-dependent protein deacetylase.
NAD+ is regenerated from NADH through the reduction
of pyruvate to lactate. LDHA plays an essential part in the
metabolism of pyruvate and NADH, and thus sustains cel-
lular NAD+ levels [47,60,61]. Therefore, SIRT1 is under
strict control of another miR-34 target, LDHA. Moreover,
studies investigating the effect of SIRT1 on LDHA found
that depletion of SIRT1 resulted in reduced transcription
of LDHA [62].
The correlation between SIRT1 and MYC has also
been investigated. A recent study identified a positive
feedback loop consisting of MYC, the nicotinamide-
phosphoribosyltransferase (NAMPT) enzyme, the SIRT1
inhibitor deleted in breast cancer 1 (DBC1) and SIRT1
[63]. This study showed that MYC activates SIRT1, which
in return promotes MYC function. MYC induces SIRT1
deacetylase activity and the MYC-induced NAMPT medi-
ates the activity of SIRT1, since the NAD+/NADH ratio is
crucial for SIRT1. Moreover, MYC may also activate SIRT1
by directly binding to the SIRT1 inhibitor DBC1. Two sep-
arate mechanisms contributing to the MYC-induced SIRT1
activation were identified: 1. MYC induces NAMPT, result-
ing in an increase in the SIRT1 cofactor NAD+. 2. The
MYC-DBC1 association facilitates SIRT1 activation. Recip-
rocally, these authors found that SIRT1-mediated deacety-
lation increases the half-life of MYC, and SIRT1 increases
MYC transcriptional activity. Although certain molecular
details remain unclear, such as the mechanisms of SIRT1
stabilization and DBC1-SIRT1 interplay, these data high-
lighted the clinical potential of targeting this feedback loop.
Another study showed the positive effect of SIRT1 on MYC
by demonstrating that the SIRT1-mediated deacetylation of
MYC could promote the association with its essential part-
ner MYC associated factor X, thereby promoting the tran-
scriptional activity of MYC [62].
A possible positive feedback loop consisting of LDHA,
MYC and SIRT1 may function collaboratively to regulate
cellular metabolism via the p53/miR-34 axis. LDHA, MYC
and SIRT1 are direct miR-34 targets and are involved in
the p53-mediated metabolic regulation. Rather than func-
tioning independently as miR-34 targets, SIRT1, MYC and
LDHA work cooperatively in p53/miR-34-mediated meta-
bolic regulation, thereby acting in a collaborative form in-
stead of in parallel.
Several other p53-induced miRNAs, such as let-7, miR-
107 and miR-200, may function as direct and indirectregulators of LDHA, MYC and SIRT1 and may broaden
our view of the collaborations between miR-34 and other
p53-induced miRNAs in metabolic regulation.
The Let-7 miRNA family is one of the most conserved
and ancient miRNAs and was found to be regulated by
p53 [64,65]. The Lin28/let-7 axis regulates glucose me-
tabolism and the RNA-binding protein Lin28 can pro-
mote malignancy through the selective inhibition of let-7
biogenesis [66,67]. MYC binds to the Lin28 promoter
and regulates its expression. Studies have found that
Lin28b plays an essential role in MYC-induced let-7 re-
pression and the MYC/let-7/Lin28 pathway is pivotal for
cellular transformation [66]. Although further research
is needed, it is possible that the let-7-MYC/Lin28 axis
plays important roles in glycolytic regulation and this
could subsequently contribute to a more complex network
involved in p53/miR-34-mediated metabolic regulation.
MiR-107 is regulated by p53 and is encoded within an in-
tron of the p53-induced pantothenate kinase 1 gene,
PANK1 [68]. Studies have found that p53-induced miR-
107 can decrease HIF-1β expression, thereby suppressing
the transcriptional response to hypoxia and inhibiting
tumor angiogenesis [69]. HIF-1β is a subunit of HIF-1 that
can modulate hypoxic responses without affecting HIF-1α
[69]. Since HIF-1 is a regulator of the miR-34 target
LDHA, p53-induced miR-107 activation may suppress
LDHA expression and lead to the suppression of glycoly-
sis. In addition to LDHA and MYC, p53/miR-107-induced
HIF-1 suppression is related to another miR-34 target,
SIRT1. SIRT1 negatively regulates HIF-1 through direct
deacetylation, and conversely, HIF-1 promotes SIRT1
transcription [70,71]. Thus, the miR-107 target HIF-1 has
tight connections with LDHA, SIRT1 and MYC. More-
over, miR-200 was also reported to regulate SIRT1 expres-
sion [72]. In summary, the collaborations among LDHA,
MYC and SIRT1 can indeed widen the window of miR-
34-induced tumor suppression (Figure 1).
Therapeutic potential of p53/miR-34-induced
metabolic targets
Since p53 is mutated in approximately 50% of human can-
cers and miR-34 is a critical component of p53 signaling
pathways, the p53/miR-34-induced metabolic targets may
have therapeutic potential. LDHA is a common target of
MYC and HIF, both of which work collaboratively in the
Warburg effect and are crucial for cellular metabolism.
Moreover, NADH-dependent LDHA regenerates NAD +
and competes with the mitochondrial NADH/NAD+
shuttle system, which is decisive for mitochondrial activity
associated with tumor metabolism [73]. Inhibition of
LDHA can limit the energy supply and consequently sup-
press the metastatic and invasive potentials of tumor cells
[46,74]. This has increased interest in the therapeutic po-

















Figure 1 Metabolic regulation by the p53/miR-34 axis and contribution of other related p53-induced miRNAs to the regulatory network.
The involvement of LDHA, MYC and SIRT1 in the metabolic regulatory network is illustrated (dotted lines), and the importance of their interaction
for miR-34-induced metabolic activity governed by p53 is suggested in the diagram.
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associated with any specific symptoms under normal con-
ditions, which indicates that inhibition of LDHA activity
could be a nontoxic therapeutic approach to induce tumor
suppression [48]. Furthermore, a number of studies have
shown that LDHA levels are associated with tumor sensi-
tivity and resistance to therapeutic agents [46,74,75].
LDHA has also been suggested as a potential target for
chemotherapies. SIRT1 and MYC are also associated with
cellular apoptosis and cell cycle arrest through the p53/
miR-34 axis [10,25]. The development of small-molecule
inhibitors of SIRT1 for the treatment of cancer is under
consideration, and activation of SIRT1 alone was sug-
gested as sufficient to induce tumor suppression in human
cancers with mutated p53 [76-78]. Moreover, increased
levels of MYC are detected in a large number of human
cancers. After the first established link between MYC and
LDHA, many other glucose metabolism genes have been
shown to be governed by MYC, such as glucose trans-
porter 1 and hexokinase 2 [79,80]. Therefore, understanding
the therapeutic effects of targeting multiple MYC-mediated
metabolic pathways may be crucial for the treatment of
cancer.
Several as yet unidentified mechanisms may play a
role in the loop consisting of SIRT1, LDHA and MYC,
and they should be considered when it comes to thera-
peutic use. For instance, how MYC overexpression
works to regulate both apoptosis and cellular metabolic
state remains an unanswered question [51]. Moreover,
the potential clinical use of SIRT1 can be complicated:SIRT1 overexpression is oncogenic in wild-type p53,
whereas it plays a tumor-suppressive role in cells with
mutated p53. Although this phenomenon has been pro-
posed to be related to p53 status [78], its underlying
mechanism requires further clarification. In addition,
the exact mechanism of how SIRT1 induces metabolic
regulation remains unknown. These uncertainties in
the roles of miR-34-induced metabolic regulation need
to be clarified.Conclusions
In this review, we described the functions of three direct
miR-34 targets and their collaboration in regulating me-
tabolism via the p53/miR-34 axis, as well as additional
p53-induced miRNAs with the same metabolic targets
as miR-34. Additionally, we discussed the significance of
these miR-34-induced metabolic targets for anticancer
therapies. In summary, metabolic regulation via the p53/
miR-34 axis may be crucial for tumor suppression and
therefore, the development of small-molecule drugs tar-
geting LDHA, SIRT1 and MYC may be a novel strategy
for anticancer therapy.Abbreviations
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